



# Viltepso in Qatar

The QCHP named-patient coordination pathway — indicative 2026

RARE DISEASE · DMD EXON 53 SKIPPING

## The clinical situation

Viltepso (viltolarsen) is a phosphorodiamidate morpholino oligomer (PMO) antisense oligonucleotide that restores partial dystrophin production in Duchenne muscular dystrophy patients amenable to exon 53 skipping. Developed by NS Pharma (Nippon Shinyaku). Weekly weight-based IV infusion, indefinitely. Eligibility is strictly genotype-gated, requires paediatric neurology oversight, a day-infusion facility, and ongoing monitoring including renal function, cardiac assessment, and motor scales (NSAA, 6MWT). Choice between Viltepso and Vyondys 53 is physician-led on availability and tolerability.

### The pathway, 5 steps

- 1 Consultation & clinical rationale.** Paediatric neurologist confirms DMD diagnosis, exon-53-skip-amenable genotype, baseline NSAA, 6MWT, cardiac and renal assessments.
- 2 Treatment-centre identification.** Hamad Medical Corporation or Sidra Medicine paediatric-neurology infusion unit confirmed as administering site.
- 3 MoPH / QCHP named-patient application.** Physician or hospital pharmacy files clinical rationale, genotyping report, patient reference, and chain-of-custody plan.
- 4 US-side sourcing & logistics.** Reserve Meds coordinates product through our US-licensed DSCSA-compliant specialty wholesale partner (NS Pharma authorised channel).
- 5 Arrival & first infusion.** Hospital pharmacy receives Viltepso; paediatric neurology team administers weekly IV infusion and manages rolling refills.

### Indicative economics

**Reference US cash-pay range:** USD 300,000–1,000,000+ per year weight-dependent (drug-only reference; Reserve Meds provides a transparent delivered quote at intake).

### Indicative first-dose timing

**7–14 days** from a complete MoPH application to first dispensation, once cohort intake opens. Indicative — not guaranteed.

## Reserve Meds's role

**Sourcing.** US-licensed specialty wholesale partner, DSCSA chain-of-custody. **Documentation.** Regulatory package for your physician and MoPH/QCHP review, keyed to exon-53-skip-amenable genotype. **Logistics.** Chain-of-custody shipment to administering hospital pharmacy on weekly-refill cadence. **Concierge case lead.** Named point of contact managing long-term refills and weight-based dose adjustments as the child grows. **We are a coordinator** — not the prescriber, not the dispensing pharmacy. All clinical decisions remain with your treating paediatric neurologist.

**COMPOSITE EXAMPLE · PRE-LAUNCH WAITLIST**

**Join the Viltepso × Qatar first-cohort waitlist.** *Our concierge reaches out as we open intake.*

[reservemed.com/access-guides/viltepso-qatar.html](https://reservemed.com/access-guides/viltepso-qatar.html)



SCAN TO JOIN

**Reserve Meds** · US-based concierge for cross-border specialty medicine. We are a coordinator; we are not the prescriber and not the dispensing pharmacy. All clinical decisions remain with the treating physician. Not medical advice.

*Reserve Meds is in pre-launch. Service availability is limited to our first cohort; all timelines published are indicative, not guarantees. Composite case examples only.*

**reservemed.com** · [hello@reservemed.com](mailto:hello@reservemed.com) · WhatsApp concierge: +1 516 528 3120 · Reviewed 2026-04-23 by Reserve Meds clinical & regulatory team